Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
Research ArticleInterventional
Open Access

Posttreatment Infarct Volumes when Compared with 24-Hour and 90-Day Clinical Outcomes: Insights from the REVASCAT Randomized Controlled Trial

F.S. Al-Ajlan, A.S. Al Sultan, P. Minhas, Z. Assis, M.A. de Miquel, M. Millán, L. San Román, A. Tomassello, A.M. Demchuk, T.G. Jovin, P. Cuadras, A. Dávalos, M. Goyal and B.K. Menon for the REVASCAT Investigators
American Journal of Neuroradiology January 2018, 39 (1) 107-110; DOI: https://doi.org/10.3174/ajnr.A5463
F.S. Al-Ajlan
aFrom the Department of Clinical Neurosciences and Department of Radiology (F.S.A.-A., A.S.A.S., P.M., Z.A., A.M.D., M.G., B.K.M.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
bDepartment of Neurosciences at King Faisal Specialist Hospital and Research Centre (F.S.A.-A.), Riyadh, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for F.S. Al-Ajlan
A.S. Al Sultan
aFrom the Department of Clinical Neurosciences and Department of Radiology (F.S.A.-A., A.S.A.S., P.M., Z.A., A.M.D., M.G., B.K.M.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A.S. Al Sultan
P. Minhas
aFrom the Department of Clinical Neurosciences and Department of Radiology (F.S.A.-A., A.S.A.S., P.M., Z.A., A.M.D., M.G., B.K.M.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for P. Minhas
Z. Assis
aFrom the Department of Clinical Neurosciences and Department of Radiology (F.S.A.-A., A.S.A.S., P.M., Z.A., A.M.D., M.G., B.K.M.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Z. Assis
M.A. de Miquel
cStroke Unit (M.A.d.M.), Neurology Department, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M.A. de Miquel
M. Millán
dStroke Unit (M.M., P.C., A.D.), Department of Neurosciences and Department of Radiology, Hospital Germans Trias, Universitat Autosome de Barcelona, Badalona (Barcelona), Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Millán
L. San Román
eStroke Unit (L.S.R.), Neurology Department, Hospital Clínic, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for L. San Román
A. Tomassello
fStroke Unit (A.T.), Neurology Department, Hospital Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Tomassello
A.M. Demchuk
aFrom the Department of Clinical Neurosciences and Department of Radiology (F.S.A.-A., A.S.A.S., P.M., Z.A., A.M.D., M.G., B.K.M.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A.M. Demchuk
T.G. Jovin
gStroke Institute (T.G.J.), Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for T.G. Jovin
P. Cuadras
dStroke Unit (M.M., P.C., A.D.), Department of Neurosciences and Department of Radiology, Hospital Germans Trias, Universitat Autosome de Barcelona, Badalona (Barcelona), Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for P. Cuadras
A. Dávalos
dStroke Unit (M.M., P.C., A.D.), Department of Neurosciences and Department of Radiology, Hospital Germans Trias, Universitat Autosome de Barcelona, Badalona (Barcelona), Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Dávalos
M. Goyal
aFrom the Department of Clinical Neurosciences and Department of Radiology (F.S.A.-A., A.S.A.S., P.M., Z.A., A.M.D., M.G., B.K.M.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Goyal
B.K. Menon
aFrom the Department of Clinical Neurosciences and Department of Radiology (F.S.A.-A., A.S.A.S., P.M., Z.A., A.M.D., M.G., B.K.M.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for B.K. Menon
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

BACKGROUND AND PURPOSE: Endovascular therapy has become the standard of care for patients with disabling anterior circulation ischemic stroke due to proximal intracranial thrombi. Our aim was to determine whether the beneficial effect of endovascular treatment on functional outcome could be explained by a reduction in posttreatment infarct volume in the Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT) trial.

MATERIALS AND METHODS: The REVASCAT trial was a multicenter randomized open-label trial with blinded outcome evaluation. Among 206 enrolled subjects (endovascular treatment, n = 103; control, n = 103), posttreatment infarct volume was measured in 204 subjects. Posttreatment infarct volumes were compared with treatment assignment and recanalization status. Appropriate statistical models were used to assess the relationship among baseline clinical and imaging variables, posttreatment infarct volume, the 24-hour NIHSS score, and functional status with the 90-day modified Rankin Scale score.

RESULTS: The median posttreatment infarct volume in all subjects was 23.7 mL (interquartile range = 68.9 mL) and 16.3 mL (interquartile range = 50.2 mL) in the endovascular treatment arm and 38.6 mL (interquartile range = 74.9 mL) in the control arm (P = .02 for endovascular treatment versus control subjects). Baseline NIHSS (P < .01), site of occlusion (P < .03), baseline NCCT ASPECTS (P < .01), and recanalization status (P = .02) were independently associated with posttreatment infarct volume. Baseline NIHSS (P < .01), time from symptom onset to randomization (P = .02), treatment type (P = .04), and recanalization status (P < .01) were independently associated with the 24-hour NIHSS scores. The 24-hour NIHSS score strongly mediated the relationship between treatment type and 90-day mRS (P < .01 for indirect effect when adjusted for age), while posttreatment infarct volume did not (P = .26).

CONCLUSIONS: Endovascular treatment saves brain and improves 90-day clinical outcomes primarily through a beneficial effect on the 24-hour stroke severity.

ABBREVIATIONS:

EVT
endovascular treatment
IQR
interquartile range

In 2015, five randomized clinical trials revolutionized stroke care by confirming the benefit of modern endovascular therapy (EVT) in patients with acute ischemic stroke due to proximal anterior circulation occlusion.1⇓⇓⇓–5 Fast reperfusion played an important role in the success of these trials, likely by saving brain that would otherwise have infarcted without reperfusion.

Although posttreatment infarct volumes are routinely used in experimental models of focal cerebral ischemia,6 human clinical trials have preferred to use ordinal scales like the modified Rankin Scale, the National Institutes of Health Stroke Scale, or the Barthel Index to primarily measure posttreatment outcomes.7⇓–9 This preference is, in part, because past human studies attempting to correlate posttreatment infarct volumes to clinical outcomes have yielded contradictory results.10,11⇓–13 On the other hand, successful recanalization has been shown to be strongly associated with improved functional outcomes and reduced mortality.14 Data from the recent Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) trial showed that the successful recanalization and reduction in posttreatment infarct volume were associated with better clinical outcome.15 The purpose of this analysis was to analyze the relationship among baseline clinical characteristics, type of treatment, recanalization status, posttreatment infarct volumes, and the 24-hour and 90-day clinical outcomes from the Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT) trial.5

Materials and Methods

Methodologic details of the REVASCAT trial have been reported elsewhere.5 Briefly, the REVASCAT trial was a prospective, multicenter, randomized, controlled, open, blinded–end point trial. Patients were randomized 1:1 to mechanical embolectomy with the stent retriever Solitaire FR (Covidien, Irvine, California) versus best medical management alone. Eligible patients were between 18 and 80 years of age, had an occlusion in the proximal anterior circulation and could be treated within 8 hours of symptom onset, and had a prestroke modified Rankin Scale score of ≤1 and a baseline score of at least 6 points on the National Institutes of Health Stroke Scale score. The main exclusion criteria on imaging were evidence of a large ischemic core, as indicated by an Alberta Stroke Program Early CT Score of <7 on CT or a score of <6 on diffusion-weighted MR imaging. All patients or their surrogates provided written informed consent. The primary outcome was disability at 90 days on the mRS.16 Secondary outcomes included centrally adjudicated infarct volumes on CT or MR imaging at 24–36 hours and vessel recanalization on CT angiography or MR angiography at 24–36 hours.

Imaging

The trial protocol included follow-up MR imaging with MR angiography or noncontrast CT with CT angiography at 24–36 hours from stroke-symptom onset.

Diffusion-weighted imaging was the technique of choice for measurement of posttreatment infarct volume. If DWI was not available, an NCCT scan was chosen for measurement. Two readers (F.S.A.-A. and P.M.) used Quantomo (Cybertrial, Calgary, Alberta, Canada)17 to delineate infarct and measure posttreatment infarct volumes (in milliliters) while being blinded to all other clinical and imaging information. Manual adjustments to delineate infarct boundaries were performed when necessary. If the infarct showed hemorrhagic conversion, the hemorrhage regions were incorporated within the boundaries of the infarct. Posttreatment infarct volume was measured with NCCT in 189 subjects and with MR imaging in 15 subjects. Successful recanalization was defined with the modified Thrombolysis in Cerebral Infarction score (2b or 3) on conventional angiography in the intervention arm and the modified arterial occlusive lesion core (2 or 3) on 24-hour CTA or MRA among subjects in the control arm.18

Statistical Analysis

Because posttreatment infarct volume did not have a normal distribution, the Wilcoxon rank sum test was used to test for differences in volumes between treatment and control subjects and between subjects achieving and not achieving recanalization.

Generalized linear regression was used to model the association between treatment and posttreatment infarct volume, adjusting for prespecified variables (age, sex, baseline NIHSS, baseline site of occlusion [internal carotid artery versus M1 or M2 of the middle cerebral artery], intravenous alteplase [yes versus no], and time from stroke onset to randomization). A cube root transformation of posttreatment infarct volume best satisfied the assumptions of this model (normality of residuals and homoscedasticity) and was used for this analysis. A similar model was used to model the association between treatment and the 24-hour NIHSS score.

A generalized linear model with log-link was used to report rate/risk ratios for functional independence (mRS 0–2 at 90 days) and 90-day mortality in the highest-versus-lowest posttreatment infarct volume quartile. Generalized linear regression with backward elimination was used to arrive at a final parsimonious model that reports the association between treatment type and 90-day mRS after adjusting for the 24-hour NIHSS score and posttreatment infarct volume. The template of Baron and Kenny19 was used to perform mediational analysis (http://www.ats.ucla.edu/stat/stata/faq/mulmediation.htm), testing whether the 24-hour NIHSS score and posttreatment infarct volume (potential mediating variables) mediate partially or completely (indirect effect) the association between treatment type and 90-day mRS. All 3 causal steps necessary for mediation analysis as proposed by Baron and Kenny were satisfied (Fig 1). All statistical analyses were performed in STATA/MP version 14.0 (StataCorp, College Station, Texas). Statistical significance was assessed at α < .05 in all analyses.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

A pictorial representation of the causal pathway in patients with acute ischemic stroke. Treatment type (EVT or control) determines posttreatment infarct volume and the 24-hour NIHSS score along with other variables such as age, sex, baseline clinical and imaging markers of stroke severity, time to treatment, and recanalization status (independent variables). Posttreatment infarct volume and the 24-hour NIHSS score (mediator variables) likely then determine 90-day mRS (dependent variable). The total effect of the independent variables on the dependent variables consists of a direct effect c′ (as shown in the image) and indirect effects.1 The indirect or mediating effect of each mediator variable on the association between independent variables and dependent variables is determined by computing the product of the regression coefficients a1 × b1 or a2 × b2 as appropriate. In our study, the 2 mediator variables (posttreatment infarct volume and the 24-hour NIHSS score) are significantly correlated. Analysis suggests that the age-adjusted 24-hour NIHSS score mediates strongly the relationship between treatment type and 90-day mRS (P < .01 for indirect effect when adjusted for age), while posttreatment infarct volume does not (P = .26).

Results

A total of 206 patients (103 in the EVT arm versus 103 in the control arm) were enrolled in the study. Median baseline NCCT ASPECTS was 7 in the EVT group and 8 in the control group. Intravenous alteplase was administered to 68.0% of patients in the EVT group and 77.7% of those in the control group. The median time from stroke onset to randomization was 225 minutes.

Median posttreatment infarct volume in all study participants was 23.7 mL (interquartile range [IQR] = 68.9 mL) and 16.3 mL (IQR = 50.2 mL) in the EVT arm and 38.6 mL (IQR = 74.9 mL) in the control arm (P = .02). Median posttreatment infarct volume in the EVT arm in recanalizers was 14.6 mL (IQR = 7.8–46.2 mL) versus 92.9 mL (IQR = 14.6–233.1 mL) in the nonrecanalizers (P = .05). The median posttreatment infarct volume in the control arm in recanalizers was 18.1 mL (IQR = 8.4–76.7 mL) versus 52.8 mL (IQR = 18.5–109.5 mL) in the nonrecanalizers (P = .02).

Baseline NIHSS score (P < .01), site of occlusion (P < .03), baseline NCCT ASPECTS (P < .01), and recanalization status (P = .02) were independently associated with posttreatment infarct volume (cube root–transformed), while age, sex, treatment type, intravenous alteplase, and time from symptom onset to randomization were not (P > .05). The baseline NIHSS score (P < .01), time from symptom onset to randomization (P = .02), treatment type (P = .04), and recanalization status (P < .01) were independently associated with the 24-hour NIHSS score, while age, sex, site of occlusion, baseline NCCT ASPECTS, and intravenous alteplase were not (P > .05). A significant correlation was seen between posttreatment infarct volume and the 24-hour NIHSS score (P < .01, Fig 2).

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Relationship between the 24-hour NIHSS score and posttreatment infarct volume in milliliters.

Distribution of posttreatment infarct volume versus 90-day mRS is shown in Fig 3. Patients in the lowest quartile for posttreatment infarct volume were 4 times more likely to achieve functional independence at 90 days (mRS 0–2) compared with patients in the highest quartile (rate ratio = 3.92; 95% CI, 0.66- 23.16). Patients in the highest quartile of posttreatment infarct volume were 4 times more likely to die at 90 days (mRS 6) compared with patients in the lowest quartile (risk ratio = 3.88; 95% CI, 1.39–10.77). In a parsimonious model obtained after including all baseline clinical and imaging variables, treatment type, and recanalization status with 90-day mRS as outcome, treatment type was not independently associated with 90-day mRS (P = .81) after adjusting for posttreatment infarct volume (P = .12), the 24-hour NIHSS score (P < .01), and age (P = .01). The Baron and Kenny mediational analysis model suggests that the 24-hour NIHSS score strongly mediates the relationship between treatment type and 90-day mRS (P < .01 for indirect effect when adjusted for age), while posttreatment infarct volume does not (P = .26).

Fig 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 3.

Relationship between 90-day mRS and posttreatment infarct volume in milliliters.

Discussion

Our results show that endovascular treatment in subjects with acute ischemic stroke and proximal anterior circulation occlusions was associated with significantly smaller posttreatment infarct volumes only when recanalization was achieved. Subjects in the control arm also achieved smaller posttreatment infarct volumes with recanalization. Our results are therefore consistent with the analysis from the ESCAPE trial that showed similar findings.15 We also found that NIHSS measured at 24 hours, though significantly correlated with posttreatment infarct volume, is a better determinant of 90-day mRS than the posttreatment infarct volume.

The causal chain in acute ischemic stroke that explains 90-day clinical outcome is complex. Baseline clinical variables such as age and baseline stroke severity as measured clinically (NIHSS) or on imaging (NCCT ASPECTS and site of occlusion) are known prognostic determinants. Early recanalization as a result of treatment (EVT, intravenous alteplase) also affects 90-day clinical outcomes. Outcomes measured earlier such as posttreatment infarct volume or the 24-hour NIHSS score may only be used as surrogates for 90-day clinical outcome if they capture the effect of these baseline clinical, imaging, and treatment variables on 90-day clinical outcome almost entirely. Our analysis shows that the age-adjusted 24-hour NIHSS score strongly mediates the relationship between treatment type and 90-day outcome and that posttreatment infarct volume does not contribute any further to mediating this relationship. Although we found a robust relationship between the 24-hour NIHSS score and posttreatment infarct volume (Fig 2), the effects of brain eloquence and other prognostic determinants such as diabetes, hypertension, or other medical comorbidities are more likely to be captured by a clinical measure such as the NIHSS compared with an imaging measure like posttreatment infarct volume. Of note, recent analysis from the ESCAPE trial showed that analysis of NIHSS trajectories from baseline to day 5 may be better than the 24-hour NIHSS score alone in determining 90-day mRS.20

Aging is a complex medical phenomenon having effects on health beyond direct effects exerted through increasing prevalence of known diseases.21 Aging is an important determinant of clinical outcomes in patients with acute ischemic stroke. Our analysis shows that age influences 90-day clinical outcome that is independent of posttreatment infarct volume and the 24-hour NIHSS score. Our analysis therefore emphasizes that surrogate outcomes in stroke such as the 24-hour NIHSS score or even posttreatment infarct volume will lose precision if patient age is not considered.

Our study has limitations. We could not do a complete exploration of the effect of all independent and mediating variables on 90-day clinical outcomes due to the limited sample size. Posttreatment infarct volumes were measured using 24- to 48-hour MR imaging or CT. MR imaging may be more sensitive than CT, and measuring infarct volumes late (even at 30 days) may offer more precise estimates of dead tissue than at 24–48 hours. Finally, although the 24-hour NIHSS score captures brain eloquence, we did not use imaging measures to better delineate eloquence.

Conclusions

Our results support primary findings from the REVASCAT trial that endovascular treatment saves brain and improves 24-hour (imaging and clinical outcomes) and 90-day clinical outcomes. The effect of EVT on 90-day clinical outcome is primarily mediated through an effect on the 24-hour NIHSS score.

Footnotes

  • Disclosures: Maria A. de Miquel—UNRELATED: Board Membership: Fundació Ictus. Andrew M. Demchuk—RELATED: Consulting Fee or Honorarium: Medtronic, Comments: honorarium for Continuing Medical Education events. Tudor G. Jovin—RELATED: Support for Travel to Meetings for the Study or Other Purposes: Fundació Ictus; UNRELATED: Consultancy: Neuravi, Johnson & Johnson; Employment: Stryker; Stock/Stock Options: FreeOx Biotech, Blockade Medical, Anaconda, Silk Road; Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: Stryker Neurovascular. Antoni Dávalos—RELATED: Grant: Covidien-Medtronic, Comments: unrestricted grant for conducting the REVASCAT trial*; UNRELATED: Payment for Lectures Including Service on Speakers Bureaus: Medtronic, Comments: less than US $2000. Mayank Goyal—UNRELATED: Grant: Medtronic, Comments: part funding for the ESCAPE trial and funding for the HERMES collaboration*; Consulting Fee or Honorarium: Medtronic, Stryker, MicroVention, Comments: for education and advice related to acute stroke; Other: GE Healthcare, Comments: licensing agreement for systems of stroke diagnosis. *Money paid to the institution.

  • REVASCAT was funded by a local independent Catalan institution (Fundació Ictus Malaltia Vascular) through an unrestricted grant from the manufacturer of the device (Covidien). This project has been partially supported by a grant from the Spanish Ministry of Health cofinanced by FEDER (Instituto de Salud Carlos III, RETICS-INVICTUS PLUS, RD 16/0019).

  • Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT01692379.

Indicates open access to non-subscribers at www.ajnr.org

References

  1. 1.↵
    1. Berkhemer OA,
    2. Fransen PS,
    3. Beumer D, et al
    . A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11–20 doi:10.1056/NEJMoa1411587 pmid:25517348
    CrossRefPubMed
  2. 2.↵
    1. Goyal M,
    2. Demchuk AM,
    3. Menon BK, et al
    ; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019–30 doi:10.1056/NEJMoa1414905 pmid:25671798
    CrossRefPubMed
  3. 3.↵
    1. Campbell BC,
    2. Mitchell PJ,
    3. Kleinig TJ, et al
    ; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372:1009–18 doi:10.1056/NEJMoa1414792 pmid:25671797
    CrossRefPubMed
  4. 4.↵
    1. Saver JL,
    2. Goyal M,
    3. Bonafe A, et al
    ; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015;372:2285–95 doi:10.1056/NEJMoa1415061 pmid:25882376
    CrossRefPubMed
  5. 5.↵
    1. Jovin TG,
    2. Chamorro A,
    3. Cobo E, et al
    ; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2296–306 doi:10.1056/NEJMoa1503780 pmid:25882510
    CrossRefPubMed
  6. 6.↵
    1. Macrae IM
    . Preclinical stroke research: advantages and disadvantages of the most common rodent models of focal ischaemia. Br J Pharmacol 2011;164:1062–78 doi:10.1111/j.1476-5381.2011.01398.x pmid:21457227
    CrossRefPubMed
  7. 7.↵
    1. Duncan PW,
    2. Jorgensen HS,
    3. Wade DT
    . Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke 2000;31:1429–38 doi:10.1161/01.STR.31.6.1429 pmid:10835468
    Abstract/FREE Full Text
  8. 8.↵
    1. Quinn TJ,
    2. Dawson J,
    3. Walters MR, et al
    . Functional outcome measures in contemporary stroke trials. Int J Stroke 2009;4:200–05 pmid:19659822
    CrossRefPubMed
  9. 9.↵
    1. Banks JL,
    2. Marotta CA
    . Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007;38:1091–96 doi:10.1161/01.STR.0000258355.23810.c6 pmid:17272767
    Abstract/FREE Full Text
  10. 10.↵
    1. Thijs VN,
    2. Lansberg MG,
    3. Beaulieu C, et al
    . Is early ischemic lesion volume on diffusion-weighted imaging an independent predictor of stroke outcome? A multivariable analysis. Stroke 2000;31:2597–602 doi:10.1161/01.STR.31.11.2597 pmid:11062281
    Abstract/FREE Full Text
  11. 11.↵
    1. Wardlaw JM,
    2. Keir SL,
    3. Bastin ME, et al
    . Is diffusion imaging appearance an independent predictor of outcome after ischemic stroke? Neurology 2002;59:1381–87 doi:10.1212/01.WNL.0000032495.71720.C3 pmid:12427888
    Abstract/FREE Full Text
  12. 12.↵
    1. Saver JL,
    2. Johnston KC,
    3. Homer D, et al
    . Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials: the RANTTAS investigators. Stroke 1999;30:293–98 doi:10.1161/01.STR.30.2.293 pmid:9933262
    Abstract/FREE Full Text
  13. 13.↵
    1. Kimura K,
    2. Sakamoto Y,
    3. Iguchi Y, et al.
    , Serial changes in ischemic lesion volume and neurological recovery after t-PA therapy. J Neurol Sci 2011;304:35–39 doi:10.1016/j.jns.2011.02.024 pmid:21397255
    CrossRefPubMed
  14. 14.↵
    1. Rha JH,
    2. Saver JL
    . The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007;38:967–73 doi:10.1161/01.STR.0000258112.14918.24 pmid:17272772
    Abstract/FREE Full Text
  15. 15.↵
    1. Al-Ajlan FS,
    2. Goyal M,
    3. Demchuk AM, et al
    ; ESCAPE Trial Investigators. Intra-arterial therapy and post-treatment infarct volumes: insights from the ESCAPE randomized controlled trial. Stroke 2016;47:777–81 doi:10.1161/STROKEAHA.115.012424 pmid:26892284
    Abstract/FREE Full Text
  16. 16.↵
    1. Saver JL
    . Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007;38:3055–62 doi:10.1161/STROKEAHA.107.488536 pmid:17916765
    Abstract/FREE Full Text
  17. 17.↵
    1. Kosior JC,
    2. Idris S,
    3. Dowlatshahi D, et al
    ; PREDICT/Sunnybrook CTA ICH study investigators. Quantomo: validation of a computer-assisted methodology for the volumetric analysis of intracerebral haemorrhage. Int J Stroke 2011;6:302–05 doi:10.1111/j.1747-4949.2010.00579.x pmid:21609412
    CrossRefPubMed
  18. 18.↵
    1. Zaidat OO,
    2. Yoo AJ,
    3. Khatri P, et al
    ; STIR Thrombolysis in Cerebral Infarction (TICI) Task Force. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke 2013;44:2650–63 doi:10.1161/STROKEAHA.113.001972 pmid:23920012
    FREE Full Text
  19. 19.↵
    1. Baron RM,
    2. Kenny DA
    . The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173–82 doi:10.1037/0022-3514.51.6.1173 pmid:3806354
    CrossRefPubMed
  20. 20.↵
    1. Sajobi TT,
    2. Menon BK,
    3. Wang M, et al
    ; ESCAPE Trial Investigators. Early trajectory of stroke severity predicts long-term functional outcomes in ischemic stroke subjects: results from the ESCAPE Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). Stroke 2017;48:105–10 doi:10.1161/STROKEAHA.116.014456 pmid:27924049
    Abstract/FREE Full Text
  21. 21.↵
    1. Bulterijs S,
    2. Hull RS,
    3. Björk VC, et al
    . It is time to classify biological aging as a disease. Front Genet 2015;6:205 doi:10.3389/fgene.2015.00205 pmid:26150825
    CrossRefPubMed
  • Received June 11, 2017.
  • Accepted after revision August 16, 2017.
  • © 2018 by American Journal of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 39 (1)
American Journal of Neuroradiology
Vol. 39, Issue 1
1 Jan 2018
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Posttreatment Infarct Volumes when Compared with 24-Hour and 90-Day Clinical Outcomes: Insights from the REVASCAT Randomized Controlled Trial
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Posttreatment Infarct Volumes when Compared with 24-Hour and 90-Day Clinical Outcomes: Insights from the REVASCAT Randomized Controlled Trial
F.S. Al-Ajlan, A.S. Al Sultan, P. Minhas, Z. Assis, M.A. de Miquel, M. Millán, L. San Román, A. Tomassello, A.M. Demchuk, T.G. Jovin, P. Cuadras, A. Dávalos, M. Goyal, B.K. Menon
American Journal of Neuroradiology Jan 2018, 39 (1) 107-110; DOI: 10.3174/ajnr.A5463

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Posttreatment Infarct Volumes when Compared with 24-Hour and 90-Day Clinical Outcomes: Insights from the REVASCAT Randomized Controlled Trial
F.S. Al-Ajlan, A.S. Al Sultan, P. Minhas, Z. Assis, M.A. de Miquel, M. Millán, L. San Román, A. Tomassello, A.M. Demchuk, T.G. Jovin, P. Cuadras, A. Dávalos, M. Goyal, B.K. Menon
American Journal of Neuroradiology Jan 2018, 39 (1) 107-110; DOI: 10.3174/ajnr.A5463
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Imaging criteria across pivotal randomized controlled trials for late window thrombectomy patient selection
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Ruptured Intracranial Aneurysms Treated with the Pipeline Embolization Device: A Systematic Review and Pooled Analysis of Individual Patient Data
  • Postprocedural Antiplatelet Treatment after Emergent Carotid Stenting in Tandem Lesions Stroke: Impact on Stent Patency beyond Day 1
  • Fast Stent Retrieval during Mechanical Thrombectomy Improves Recanalization in Patients with the Negative Susceptibility Vessel Sign
Show more INTERVENTIONAL

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2020 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2021 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire